e-learning
resources
ERJ
2017
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The risk of mycobacterial infections associated with inhaled corticosteroid use
Sarah K. Brode, Michael A. Campitelli, Jeffrey C. Kwong, Hong Lu, Alex Marchand-Austin, Andrea S. Gershon, Frances B. Jamieson, Theodore K. Marras
Source:
Eur Respir J, 50 (3) 1700037; 10.1183/13993003.00037-2017
Journal Issue:
September
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Sarah K. Brode, Michael A. Campitelli, Jeffrey C. Kwong, Hong Lu, Alex Marchand-Austin, Andrea S. Gershon, Frances B. Jamieson, Theodore K. Marras. The risk of mycobacterial infections associated with inhaled corticosteroid use. Eur Respir J, 50 (3) 1700037; 10.1183/13993003.00037-2017
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Debate -Tuberculosis: Rolling out of new drugs without diagnostic capacities
Panel discussion on unprecedented progress in shortening treatment for TB: Evidence to date, and future possibilities
Related content which might interest you:
Inhaled corticosteroids and the increased risk of non-tuberculous mycobacteria infection
Source: International Congress 2019 – Exploring the link between inhaled corticosteroids and respiratory infection
Year: 2019
Assessing the incidence pattern of pneumonia among COPD patients with or without exposure to inhaled steroids
Source: Annual Congress 2007 - Epidemiology of COPD
Year: 2007
Role of inhaled corticosteroids on recurrent bronchial infection by potentially pathogenic bacteria in patients with COPD
Source: Virtual Congress 2020 – COPD : inhaled corticosteroids, bronchodilators and eosinophils
Year: 2020
High prevalence of yeasts and mycosis infections in a COPD population after long term use of inhaled steroid
Source: Eur Respir J 2005; 26: Suppl. 49, 407s
Year: 2005
Incidence of oropharyngeal candidiasis during treatment with high doses of inhaled corticosteroids
Source: Eur Respir J 2002; 20: Suppl. 38, 111s
Year: 2002
Long-term effects of inhaled corticosteroids on sputum bacterial and viral loads in COPD
Source: Eur Respir J, 50 (4) 1700451; 10.1183/13993003.00451-2017
Year: 2017
Inhaled drugs as risk factors for community-acquired pneumonia
Source: Eur Respir J 2010; 36: 1080-1087
Year: 2010
Comparing pneumonia incidence in COPD patients treated with or without inhaled corticosteroid
Source: Virtual Congress 2021 – Inhaled treatments for COPD: real-world data
Year: 2021
An economic evaluation of adding inhaled corticosteroids to systemic corticosteroids for treating acute asthma exacerbations
Source: International Congress 2019 – Severe acute asthma and troublesome wheezing
Year: 2019
Influence of inhaled bronchodilator therapy on bacterioexcretion and LQ in patients with pulmonary TB infection with concomitant broncho-obstructive syndrome
Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions
Year: 2011
Inhaled corticosteroid use is associated with lower mortality for subjects with COPD and hospitalised with pneumonia
Source: Eur Respir J 2010; 36: 751-757
Year: 2010
Systemic corticosteroid and inhalation corticosteroid therapy are associated with nontuberculous mycobacterial pulmonary disease
Source: International Congress 2015 – Non-tuberculous mycobacteria and molecular microbiology
Year: 2015
Regular use of inhaled corticosteroids and the long-term prevention of hospitalisation for asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 8s
Year: 2002
Are COPD patients with pneumonia who are taking inhaled corticosteroids at higher risk of dying?
Source: Eur Respir J 2011; 37: 1-3
Year: 2011
Inhaled drugs as risk factors for community-acquired pneumonia
Source: Annual Congress 2010 - The spectrum of lower respiratory tract infections: risk factors of poor outcome and diagnostic tools
Year: 2010
Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results
Source: Eur Respir J 2009; 34: 641
Year: 2009
Effect of maintenance oral corticosteroids on risk factors for frequent exacerbations in a severe adult asthma population
Source: Virtual Congress 2020 – Severe asthma phenotypes and outcomes
Year: 2020
Comparative risks of chronic inhaled corticosteroids and macrolides for bronchiectasis
Source: Eur Respir J, 54 (1) 1801896; 10.1183/13993003.01896-2018
Year: 2019
Effect of different asthma treatments on risk of cold-related exacerbations
Source: Eur Respir J 2011; 38: 584-593
Year: 2011
Estimation of risk of osteoporosis based on inhaled and oral corticosteroids
Source: Eur Respir J 2002; 20: Suppl. 38, 409s
Year: 2002
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept